For Korean Life Science startups, financing challenges are structural. We analyze the bridge to Canadian markets as a catalyst for global R&D scale.
Kowest Capital provides the essential expertise required for Life Science companies to navigate the complexities of Canadian and US public markets. We help SMEs unlock North American liquidity and global investment through proven exchange platforms.
Comprehensive readiness and execution strategies for listing on the TSX, TSX-V, or CSE.
Building institutional depth and connecting your science with specialized venture capital pools.
Providing seasoned CFO and Advisor support to strengthen your governance for public entry.
Navigating unique Canadian pathways like the Capital Pool Company (CPC) program for early public entry.
Domestic VCs allocate disproportionately to later-stage or revenue-oriented firms, leaving early-stage R&D under-capitalized.
Firms without immediate revenue faces significant valuation discounts compared to global peers on the TSX or NASDAQ.
Stringent domestic listing requirements often exceed a decade for startups, delaying critical liquidity.
High cumulative costs over decade-long development cycles often exhaust available capital before critical clinical milestones are reached, creating a “funding gap” for novel products.
Current Status:
Korean Domestic MarketsCanada offers a unique ecosystem designed for venture-stage companies to go public even pre-revenue. This is your chance to invite visitors to contact you. Tell them you’ll be happy to answer all their questions as soon as possible.